A phase III clinical study is also underway in combination with a PARP inhibitor (Niraparib), VEGFR inhibitor (Bevacizumab), and an immune checkpoint inhibitor (TSR-042) to treat platinum-resistant ovarian cancer (NCT03574779). Here, PARP1 is linked to ovarian carcinoma.